The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials

doi:10.1371/journal.pone.0267706

科研成果详情

名称	The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials
作者	Liu, Zhi-Ming 1; Zhang, Min2,3; Zong, Yuan 1; Zhang, Ding 1; Shen, Zhu-Bin 1; Guan, Xiao-Qing 1; Yin, Fei 1
发表期刊	PLOS ONE
语种	英语
原始文献类型	Review
摘要	Background Glucocorticoid-induced osteoporosis (GIOP) is the most common secondary osteoporosis, alendronate (ALE) and teriparatide (TPTD) are widely used in the treatment of GIOP. However, which of these two drugs has a better curative effect needs the support of evidence-based medicine. Methods We searched PubMed, Embase, Cochrane Library, Web of Science, and Google Scholar for randomized controlled trials of ALE and TPTD in the treatment of glucocorticoid-induced osteoporosis until February 2022. These patients included in the study took glucocorticoid doses greater than 7.5 mg/d for more than 3 months before treatment with ALE and TPTD. The risk ratio (RR) and its 95% confidence interval (CI) are used as the influence index of discontinuous data, and the standardized mean difference (SMD) and its 95% CI are used as the influence index of continuous data. Results A total of 4102 patients were enrolled in all 5 studies that met the admission criteria. We found that compared with ALE, TPTD could reduce the rate of new vertebral fracture (RR = 0.13, 95% CI: 0.05-0.34, P<0.00001). TPTD increased LS bone mineral density (BMD) (0.53, 95% CI 0.42-0.64, P<0.00001), TH BMD (0.17, 95% CI 0.05-0.28, P = 0.004) and FN BMD (0.17, 95% CI 0.05-0.29, P = 0.006) compared to ALE. However, there was no significant difference in the incidence of non-vertebral fracture and adverse events between the two groups. Conclusions Compared with ALE, TPTD is an effective drug to reduce vertebral fracture risk in patients with GIOP. Furthermore, long-term use of TPTD can increase the bone mineral density of LS, FN, and TH.
出版者	PUBLIC LIBRARY SCIENCE
出版地	SAN FRANCISCO
ISSN	1932-6203
卷号	17
期号	5
DOI	10.1371/journal.pone.0267706
页数	15
WOS类目	Multidisciplinary Sciences
WOS研究方向	Science & Technology - Other Topics
WOS记录号	WOS:000841472800009
收录类别	SCIE
发布日期	2022-05-31
PubMed ID	35639783
引用统计	被引频次：1[WOS] [WOS记录] [WOS相关记录]
文献类型	其他
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/154711
专题	附属第二医院_新生儿科第二临床医学院，附属第二医院、育英儿童医院
通讯作者	Yin, Fei
作者单位	1.Jilin Univ, Dept Spine Surg, China Japan Union Hosp, Changchun 130033, Peoples R China; 2.Wenzhou Med Univ, Affiliated Hosp 2, Dept Neonatol, Wenzhou 325027, Peoples R China; 3.Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325027, Peoples R China
推荐引用方式 GB/T 7714	Liu, Zhi-Ming,Zhang, Min,Zong, Yuan,et al. The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials. 2022.